198
Participants
Start Date
December 11, 2019
Primary Completion Date
January 9, 2025
Study Completion Date
January 9, 2025
HB-201 intravenous administration.
Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
HB-202 intravenous administration alternating with HB-201 intravenous administration.
Dose / Schedule determined by 3+3 dose escalation (3 to 6 patients per cohort).
HB-201 intravenous administration + standard of care regimen including pembrolizumab.
Dose Expansion
HB-202 / HB-201 alternating intravenous administration + pembrolizumab.
Dose Expansion
HB-202 / HB-201 alternating intravenous administration + standard of care regimen including pembrolizumab.
Dose Expansion
HB-201 or HB-201/HB-202 alternating treatment using CD8 PET Tracer (Zr-Df-IAB22M2C)
Dose escalation; 10 patients
Amsterdam UMC, Locatie VUMC, Amsterdam
Hospital de la Santa Creu i Sant Pau, Barcelona
Grossman School of Medicine, New York
Memorial Sloan Kettering Cancer Center, New York
Icahn School of Medicine at Mount Sinai, New York
Montefiore-Einstein Center for Cancer Care, The Bronx
Perlmutter Cancer Center at NYU Langone Hospital-Long Island, New York
University of Virgina Health System, Charlottesville
Hospital Universitario Fundacion Jimenez Diaz, Madrid
Centro Integral Oncologico Clara Campal, Madrid
Greenville Hospital System University Medical Center (ITOR), Greenville
Sylvester Comprehensive Cancer Center, Miami
O'Neal Comprehensive Cancer Center at UAB, Birmingham
Hospital Universitario Virgen del Rocio, Seville
Cleveland Clinic, Cleveland
Henry Ford Hospital, Detroit
University of Iowa Hospitals & Clinics, Iowa City
Froedtert Hospital and Medical College of Wisconsin, Milwaukee
Loyola University Medical School, Maywood
University of Chicago Medical Center, Chicago
Washington University School of Medicine, St Louis
University of Kansas Medical Center, Fairway
Nebraska Methodist Hospital, Omaha
University of Arkansas for Medical Sciences, Cancer Institute, Clinical Trials Office, Fayetteville
University of Oklahoma Health Sciences Center, Oklahoma City
The University of Texas MD Anderson Cancer Center, Houston
Banner MD Anderson Cancer Center, Gilbert
USC/Norris Comprehensive Cancer Center, Los Angeles
UCLA (University of California, Los Angeles), Los Angeles
Providence Portland Medical Center, Portland
Hospital Universitario Virgen Macarena, Seville
Rutgers Cancer Institute of New Jersey, New Brunswick
Hospital Universitari Vall d'Hebron, Barcelona
Hospital Clinic de Barcelona, Barcelona
Lead Sponsor
Hookipa Biotech GmbH
INDUSTRY